- Teva Pharmaceutical press release (TEVA): Q4 Non-GAAP EPS of $0.96 beats by $0.32.
- Revenue of $4.71B (+11.3% Y/Y) beats by $380M.
- FY26 revenue consensus of $16.99B, EPS consensus of $2.77
-
2026 Business Outlook:
- Revenues of $16.4 – $16.8 billion
- Non-GAAP
Teva Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.32, revenue of $4.71B beats by $380M
